Tianyin Pharmaceuticals Receives China’s SFDA Approval for Its Anti-Diabetic Drug Gliclazide

In 2010, there were 95 million cases of diabetes in China, of which, 52 million and 43 million were found in rural and urban areas, respectively.

Read more »